Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
86.70
-1.40 (-1.59%)
Jul 31, 2026, 4:08 PM HKT

Innovent Biologics Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
13,04213,0429,4226,2064,5564,270
Revenue Growth
14.17%38.42%51.82%36.21%6.71%11.08%
Gross Profit
9,9989,9987,1634,3993,1753,045
Operating Income
733.62733.62-123.3-1,564-3,123-2,703
Net Income
813.57813.57-94.63-1,028-2,179-2,729
Earnings Per Share
0.470.47-0.06-0.66-1.46-1.88
EPS Growth
-30.34%-----

Revenue by Geography

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
The People's Republic of China (PRC)
12,06912,0698,9835,7534,1333,968
United States of America ("USA")
380.61380.61411.59442.6411.03261.64
Europe
571.81571.81----
Other
19.6319.6326.8810.1212.81-
Total
13,04213,0429,4226,2064,5564,270

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
18,23118,2317,88410,9709,1669,015
Total Debt
2,8162,8162,8313,6213,2292,497
Net Cash (Debt)
15,41615,4165,0537,3495,9386,518
Net Cash Growth
150.22%205.10%-31.25%23.77%-8.91%-5.73%
Net Cash Per Share
8.858.853.104.713.984.48

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
10,00110,0011,287147.81-1,919-2,025
Capital Expenditures
-269.88-269.88-965.67-1,119-896.9-1,066
Free Cash Flow
9,7319,731321.36-971.58-2,816-3,090
Free Cash Flow Growth
572.18%2928.12%----

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
76.66%76.66%76.03%70.89%69.67%71.32%
Operating Margin
5.63%5.63%-1.31%-25.20%-68.54%-63.31%
Pretax Margin
6.43%6.43%-0.83%-18.44%-47.64%-61.87%
Profit Margin
6.24%6.24%-1.00%-16.56%-47.83%-63.91%
FCF Margin
74.62%74.62%3.41%-15.65%-61.80%-72.38%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
165.77146.09----
Forward PE
58.8642.67----
P/FCF Ratio
13.9412.21175.32---
PS Ratio
10.409.115.9810.149.9813.46